Lateral Pharma
Melbourne, Australia· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
An Australian biotech developing first-in-class LanCL-targeting therapies for neuropathic pain, neurodegeneration, and healthy ageing.
OncologyImmunologyNeurologyPainInfectious Disease
Technology Platform
Stressed Cell Protective (SCP) platform developing peptide and small molecule drugs that activate LanC-like (LanCL) proteins, a novel endogenous pathway that protects cells from stress, inflammation, and damage.
Opportunities
The LanCL pathway offers a first-in-class, disease-modifying approach in neuropathic pain (non-opioid) and neurodegeneration, with potential expansion into large markets like healthy ageing (healthspan) and host-directed therapies for respiratory infections.
Risk Factors
Clinical risk: LAT9997 must demonstrate efficacy in larger trials; platform risk: novel LanCL target is unproven in late-stage development; financial risk: as a private, pre-revenue company, dependent on raising capital in a competitive funding environment.
Competitive Landscape
In neuropathic pain, competes with neuromodulators, antidepressants, and novel mechanisms; differentiation is non-opioid, potentially curative LanCL targeting. In Alzheimer's, enters a field dominated by amyloid/tau-targeting biologics; differentiation is neuroprotection via stress pathway modulation.